Trials / Terminated
TerminatedNCT01018563
An Open Label Extension Study of the Efficacy of MORAb-003
An Open Label Extension Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 3 (actual)
- Sponsor
- Morphotek · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
An open label extension of the MORAb-003-002 study in order to continue the active patients in the MORAb-003-002 study on maintenance MORAb-003 infusions after the main study is closed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MORAb-003 | Dose group to be determined by dose assigned in main study and patient's weight. Intravenous infusions are given every 3 weeks. |
Timeline
- Start date
- 2010-01-13
- Primary completion
- 2013-03-05
- Completion
- 2013-03-05
- First posted
- 2009-11-23
- Last updated
- 2021-12-08
- Results posted
- 2021-12-08
Locations
3 sites across 2 countries: United States, Germany
Source: ClinicalTrials.gov record NCT01018563. Inclusion in this directory is not an endorsement.